Ceftobiprole Medocaril Sodium for Injection

	Minimum Inhibitory Concentrations (mcg/mL)			Disk Diffusion^a (zone diameters in mm)
Pathogen^b	S	I	R	S	I	R
Staphylococcus aureus (includes methicillin resistant isolates)	≤ 2	4	≥ 8	≥ 16	14-15	≤ 13
Streptococcus pneumoniae	≤0.5	1	≥2	-	-	-
Streptococcus pyogenes^c	≤ 0.5	-	-	≥ 24	-	-
Enterobacterales^d	≤ 0.25	0.5	≥ 1	≥ 23	21-22	≤ 20
Haemophilus influenzae and parainfluenzae	≤ 0.25	0.5	≥ 1	-	-	-

S = susceptible; I = intermediate; R = resistant
^a For disk diffusion, use paper disks impregnated with 5 mcg ceftobiprole.
^b Susceptibility interpretive criteria are based on a dose of 667 mg ceftobiprole medocaril sodium every 6 hours on days 1 to 8 and every 8 hours from day 9 for patients with Staphylococcus aureus bacteremia (SAB) and a dose of 667 mg every 8 hours for patients with acute bacterial skin and skin structure infections (ABSSSI) and community acquired bacterial pneumonia (CABP) in adult patients with creatinine clearance > 50 mL/min); 667 mg of ceftobiprole medocaril sodium is equivalent to 500 mg of ceftobiprole.
^c The absence of resistant isolates precludes defining any results other than “Susceptible”. Isolates yielding MIC results other than “Susceptible” should be submitted to a reference laboratory for further testing.
^d Clinical efficacy was shown for Klebsiella pneumoniae in patients with ABSSSI and for Escherichia coli and Klebsiella pneumoniae in patients with CABP